Inovio Pharmaceuticals (NASDAQ: INO) — Perfil da empresa, notícias e dados financeiros
Inovio Pharmaceuticals develops DNA-based immunotherapies and vaccines for cancer and infectious diseases, aiming for global health impact.
Inovio Pharmaceuticals
Inovio Pharmaceuticals (NASDAQ:INO) is a biotechnology firm focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines for infectious diseases and cancer. The company leverages its proprietary plasmid DNA technology to stimulate robust and specific immune responses. Inovio's pipeline includes candidates for HPV-associated diseases, cancer, and infectious diseases such as COVID-19. With a commitment to global health, Inovio aims to innovate and make accessible new vaccines and therapies that can change the course of human diseases. Additionally, the company collaborates with industry leaders and organizations worldwide to advance and expand its reach in public health.
Resumo
Operações
Produtos e/ou serviços de Inovio Pharmaceuticals
- INO-4800, a DNA vaccine candidate for COVID-19, designed to precisely target the SARS-CoV-2 virus.
- VGX-3100, a DNA-based immunotherapy for the treatment of HPV-related precancers.
- Cellectra, a proprietary smart device for delivering DNA vaccines and therapeutics directly into the skin.
- INO-5401, a combination therapy targeting glioblastoma, a lethal brain cancer, using multiple immunotherapeutic agents.
- INO-5151, a DNA-based therapy aimed at treating prostate cancer by targeting specific cancer antigens.
- DNA medicines platform, providing rapid development of vaccines and therapies for infectious diseases and cancer.
equipe executiva do Inovio Pharmaceuticals
- Jacqueline E. SheaCEO, President & Director
- Peter D. KiesChief Financial Officer
- Michael SumnerChief Medical Officer & Head of Development
- Laurent M. HumeauChief Scientific Officer & Chairman of the Scientific Advisory Board
- Robert L. CrottyGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- Jennie WillsonDirector of Communications
- E. J. BrandrethSenior Vice President of Quality Assurance
- Jeffrey SkolnikSenior Vice President of Clinical Development
- Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply Management
- Shawn D. BridySenior Vice President of Business Development
Últimas notícias sobre a Inovio Pharmaceuticals
Histórico de dividendos
Dividendos por ação pagos pela Inovio Pharmaceuticals, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2017 | — | — | — | $0.2760 |
Principais indicadores financeiros
Resultados divulgados pela Inovio Pharmaceuticals, em USD.
- Cap. de mercado
- 92 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 65,3 mil | -86,8 mi | -84,9 mi | |
| 217,8 mil | -112,4 mi | -107,3 mi | |
| 832 mil | -143,9 mi | -135,1 mi | |
| 10,3 mi | -267,6 mi | -279,8 mi |